CTKB
Cytek Biosciences Inc
NASDAQ: CTKB · HEALTHCARE · MEDICAL DEVICES
$4.12
-5.54% today
Updated 2026-06-05
Market cap
$559.19M
P/E ratio
—
P/S ratio
2.74x
EPS (TTM)
$-0.58
Dividend yield
—
52W range
$3 – $6
Volume
0.8M
WallStSmart proprietary scores
41
out of 100
Grade: D
Sell
Investment rating
7.3
Growth
B+8.5
Quality
A2.0
Profitability
F6.7
Valuation
B4/9
Piotroski F-Score
Moderate
2.5
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$5.69
+38.11%
12-Month target
—
—
Intrinsic (DCF)
$7.62
Margin of safety
+42.78%
1 Strong Buy1 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ 42.78% below intrinsic value
+ Debt/equity 0.11x — low leverage
Risks
- Thin margins at -36.20%
- Negative free cash flow $-4.90M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $164.04M | $193.01M | $200.45M | $201.49M | $204.17M |
| Net income | $2.58M | $-12.15M | $-6.02M | $-66.54M | $-18.87M |
| EPS | — | — | — | — | $-0.58 |
| Free cash flow | $-22.10M | $454000.00 | $21.85M | $-8.77M | $-4.90M |
| Profit margin | 1.57% | -6.29% | -3.00% | -33.02% | -36.20% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-18 | YAN, MING | Sale | 9,480 | — |
| 2026-05-18 | YAN, MING | Sale | 4,908 | — |
| 2026-05-18 | YAN, MING | Sale | 4,108 | — |
Peer comparison
Smart narrative
Cytek Biosciences Inc trades at $4.12. Our Smart Value Score of 41/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.45, it sits in the grey zone. TTM revenue stands at $204.17M. with profit margins at -36.20%. Our DCF model estimates intrinsic value at $7.62.
Frequently asked questions
What is Cytek Biosciences Inc's stock price?
Cytek Biosciences Inc (CTKB) trades at $4.12, on a P/S of 2.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Cytek Biosciences Inc overvalued?
Cytek Biosciences Inc carries a Smart Value Score of 41/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $7.62 versus the $4.12 price, a 42.8% margin of safety on a cash flow basis.
What is the price target of Cytek Biosciences Inc (CTKB)?
The 12-month analyst consensus target is $5.69, about 38.1% above the current $4.12. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Cytek Biosciences Inc (CTKB)?
Our DCF model estimates intrinsic value at $7.62, a +42.8% margin of safety versus today's $4.12. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Cytek Biosciences Inc's revenue?
Cytek Biosciences Inc's trailing twelve-month revenue is $204.17M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Cytek Biosciences Inc's Altman Z-Score is 2.45, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.74x
ROE-22.59%
Beta1.19
50D MA$4.34
200D MA$4.48
Shares out0.13B
Float0.10B
Short ratio—
Avg volume0.8M
Performance
1 week+0.00%
1 month+21.91%
3 months+2.00%
YTD-19.01%
1 year—
3 years—
5 years—